Background: Sub-anesthetic doses of the non-competitive N-methyl-D-aspartate receptor (NMDA-R) antagonist ketamine evoke transient psychotomimetic effects, followed by persistent antidepressant effects in treatment-resistant depressed patients and rodents through still poorly understood mechanisms. Since phencyclidine (PCP) disinhibits thalamo-cortical networks by blocking NMDA-Rs on GABAergic neurons of the reticular thalamic nucleus (RtN), we examined ketamine's actions in the same areas. Methods: Single units and local field potentials were recorded in chloral hydrate anesthetized male Wistar rats. The effects of cumulative ketamine doses (0.25e5 mg/kg, i.v.) on neuronal discharge and oscillatory activity were examined in RtN, mediodorsal and centromedial (MD/CM) thalamic nuclei, and layer VI of the medial prefrontal cortex (mPFC). Results: Ketamine (1, 2 and 5 mg/kg, i.v.) significantly decreased the discharge of MD/CM, RtN and layer VI mPFC pyramidal neurons. Simultaneously, ketamine decreased the power of low frequency oscillations in all areas examined and increased gamma oscillations in mPFC and MD/CM. Lower ketamine doses (0.25 and 0.5 mg/kg, i.v.) were ineffective. Conclusions: As observed for PCP, ketamine markedly inhibited the activity of RtN neurons. However, unlike PCP, this effect did not translate into a disinhibition of MD/CM and mPFC excitatory neurons, possibly due to a more potent and simultaneous blockade of NMDA-Rs by ketamine in MD/CM and mPFC neurons. Hence, the present in vivo results show that ketamine evokes an early transient inhibition of neuronal discharge in thalamo-cortical networks, following its rapid pharmacokinetics, which is likely associated to its psychotomimetic effects. The prolonged increase in gamma oscillations may underlie its antidepressant action.
Introduction
Major depressive disorder (MDD) is a severe psychiatric disorder with a high prevalence and socio-economic impact worldwide (GBD, 2015; Kessler et al., 2003) . Current monoaminergic antidepressants show slow onset of antidepressant action and limited efficacy (Penn and Tracy, 2012; Rush et al., 2006; Stahl, 2000; Trivedi et al., 2006) . Therefore, there is an urgent need to develop faster and more effective treatments. A substantial amount of evidence implicates the glutamatergic system in the pathophysiology and treatment of mood disorders (Beneyto et al., 2007; Feyissa et al., 2009; Hasler et al., 2007; Sanacora, 2009; Sanacora et al., 2012; Skolnick et al., 1996) . In this regard, functional N-methyl-Daspartate receptor (NMDA-R) antagonists exhibit antidepressantlike effects in rodents (Skolnick et al., 2009) .
Sub-anesthetic doses of non-competitive NMDA-R antagonists such as phencyclidine (PCP) and ketamine are extensively used as pharmacological models of schizophrenia due to their ability to reproduce the symptoms of the illness in healthy individuals and to aggravate them in patients (Krystal et al., 2003) . PCP, ketamine and MK-801 (dizocilpine) also induce behavioral alterations in experimental animals, sensitive to antipsychotic treatment (Geyer et al., 2001 ). In addition, ketamine has been shown to evoke immediate and persistent antidepressant responses in groups of treatmentresistant depressed patients and antidepressant-like effects in rodents (Browne and Lucki, 2013; Mion and Villevieille, 2013; Monteggia and Zarate, 2015; Newport et al., 2015; Singh et al., 2016; Zarate et al., 2006) . Given ketamine's psychotomimetic action and abuse potential (Sanacora et al., 2017) , there is a need to understand its mechanism of action. This will help to develop more effective antidepressant drugs, also contributing to clarify the brain networks involved in its psychotomimetic action. Non-competitive NMDA-R antagonists may preferentially block NMDA-R in GABA neurons, thereby producing an overall increase in excitability in cortical and subcortical regions, (Coyle, 2012) . Indeed, these agents enhance excitatory neurotransmission and glutamate release in rodent medial prefrontal cortex (mPFC) (Homayoun and Moghaddam, 2007; Jackson et al., 2004; Kargieman et al., 2007; Moghaddam et al., 1997) . This action may involve the blockade of NMDA-R on cortical GABA interneurons, as shown for MK-801 (Homayoun and Moghaddam, 2007) , and/or in GABA neurons of the reticular nucleus of the thalamus (RtN), as shown for PCP (Troyano-Rodriguez et al., 2014) . The RtN is composed exclusively of GABA neurons that provide feed-forward inhibition to the rest of (excitatory) thalamic nuclei (Pinault, 2004; Steriade, 2001) . Hence, NMDA-R blockade by PCP in RtN immediately translates into a disinhibition of excitatory thalamocortical neurons and the subsequent increase of thalamocortical excitatory inputs (Santana et al., 2011) , an effect that may contribute to the increase of pyramidal neuron discharge evoked by PCP in mPFC (Kargieman et al., 2007) .
Several observations support a key role for the ventral anterior cingulate cortex in humans or its homologous region in rodents, the infralimbic (IL) subdivision of mPFC, in the mechanism of action of ketamine (Downey et al., 2016; Fuchikami et al., 2015; Li et al., 2016) .
Likewise, a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-R) stimulation in IL evokes antidepressant-like effects in rats (Gasull-Camos et al., 2017) . In addition to blocking NMDA-R, ketamine may also activate AMPA-R through its metabolite (2R,6R)-hydroxynorketamine (Autry et al., 2011; Fukumoto et al., 2016; Koike and Chaki, 2014; Li et al., 2010; Maeng et al., 2008; Zanos et al., 2016) and evoke longlasting biochemical/structural changes (Duman and Aghajanian, 2012; Li et al., 2010; Popp et al., 2016 ) that putatively could be involved in the long-lasting antidepressant effects of the drug (Mion and Villevieille, 2013) . Given our previous observations on PCP; the present study was designed to investigate the actions of ketamine on thalamo-cortical networks using in vivo electrophysiology in anesthetized rats. The main aim was to increase the knowledge of the brain circuitry affected by ketamine and to elucidate the mechanism(s) underlying its psychotomimetic and antidepressant effects. We have used the same experimental conditions and setting as previous electrophysiological studies from this laboratory on PCP (Kargieman et al., 2007; Santana et al., 2011; Troyano-Rodriguez et al., 2014) , which allows a direct comparison of the effects of the two NMDA-R antagonists in rat brain.
Methods and materials

Animals
Animal care followed EU regulations (directive 2010/63 of 22 September 2010) and was approved by the Institutional Animal Care and Use Committee. Male albino Wistar rats (Charles River; 250e350 g) were kept under standard temperature (22 ± 1.5 C) and humidity (55e65%) controlled laboratory conditions with food and water ad libitum in a 12 h:12 h light/dark cycle.
Drugs
(R,S)-Ketamine (Ketolar 50 mg/ml, Pfizer) was dissolved in 0.9% saline (0.5 mg/ml) and administered at cumulative doses of 0.25, 0.5, 1, 2 and 5 mg/kg, chosen based on the pharmacokinetic profile of ketamine to achieve brain exposures in rats comparable to the clinical concentrations (Shaffer et al., 2014) . All drugs and vehicles (veh) were administered intravenously (i.v.) through a femoral vein cannula in chloral hydrate anesthetized rats. The following dosing paradigms were used (injection every 5 min): Veh/Veh1/Veh2/ Veh3, Veh/Ket0.25/Ket0.5 and Veh/Ket1/Ket2/Ket5 (n ¼ 5e15 per group, Supplementary Table 1).
Surgical procedure
Rats were anesthetized with chloral hydrate (400 mg/kg, i.p. followed by 50e70 mg/kg per h i.p. using a perfusion pump and supplemented by 0.2 ml i.v. injection if required). A femoral vein cannula (P20 tubing) was inserted, and the rats were placed in a stereotaxic frame (David Kopf, Tujunga, CA) and kept at 37 C via a heating pad (Cibertec RTC1, Madrid, Spain). One small hole was drilled into the skull to accommodate a glass electrode in either the RtN, the MD/CM or layer VI of the mPFC (coordinates relative to 
Electrophysiological recordings
Single unit and local field potential (LFP) recordings in the RtN, MD/CM and layer VI of the mPFC were performed as previously described (Kargieman et al., 2007; Santana et al., 2011; TroyanoRodriguez et al., 2014) . Additional LFPs were recorded in the contralateral IL, simultaneously with single unit and LFP recordings with glass electrodes, using unipolar stainless steel electrodes (single unit band-pass filter: 30 Hz-10 kHz; LFPs band-pass filter of 0.1e100 Hz in RtN and MD/CM and 0.1e200 Hz in mPFC).
All recorded units in the mPFC were identified as corticothalamic neurons by antidromic activation from the MD (electrical stimulation of the MD: square-wave pulses À0.5 ms duration, 250e500 mA intensity-delivered at frequencies of 3e10 Hz) using a bipolar concentric tungsten electrode (TM53CCINS, World Precision Instruments Inc., USA) on basis of their fixed latency and collision with a spontaneous spike as described in a previous study (latency: 18.5 ± 3.4 ms, n ¼ 29) (Pirot et al., 1994) . A scheme of the recording areas, their reciprocal connectivity and representative examples of single unit recordings is given in Fig. 1. 
Data analysis
To assess the acute effects of ketamine at different doses, each treatment was recorded for 5 min, of which the last 2 min periods were averaged and normalized to a stable 5 min baseline for the firing rate (Figs. 2A, 3A and 4A) and to the last 1 min baseline for the oscillatory activity (Figs. 2B, 3C and 4B) . Similarly, to visualize prolonged effects of the higher dose administrated, the last 2 min period per 5 min bins were averaged and normalized to a stable 5 min baseline for the firing rate (Fig. 3B ) and to the last 1 min baseline for the oscillatory activity (Figs. 3DeE, 4CeD) . Analysis of single unit recordings was carried out importing the signals to MATLAB (MathWorks, Natick, Massachusetts) for off-line analysis. A burst episode was defined as the occurrence of two or more spikes with an interspike interval of 4 ms for the MD, 10 ms for the RtN and <45 ms for the mPFC (Kargieman et al., 2007; Laviolette et al., 2005; Santana et al., 2011; Sittig and Davidowa, 2001; Troyano-Rodriguez et al., 2014; Ushimaru et al., 2012) . LFP recordings were Fast Fourier transformed to yield the power of oscillatory activity of 1 min signal intervals (Spike 2 software version 7.10, Cambridge Electronic Design Limited, UK). LFP signals were divided into 5 main frequency bands of oscillations: delta 0.15e4, theta 4e8 Hz, alpha 8e12 Hz, beta 12e30 Hz, gamma 30e90 Hz or low gamma 30e48 Hz. Data from 48 to 52 Hz and 58e62 Hz frequency range was discarded due to electric noise. One way repeated measures analysis of variance (RM-ANOVA) as between-subject factor and treatment or time as within-subject factor followed by Holm-Sidak post-hoc test were used to assess the differences between baseline and post-injection values of firing rate and power of the oscillations within the same treatment group (Sigma Plot, version 11.0). Data are presented as mean ± standard error of the means (S.E.M.) with a p value of <0.05 being considered significant.
Tissue and plasma collection
Plasma and brain concentrations of (R,S)-ketamine, (R,S)-norketamine and (2R,6R)-hydroxynorketamine (HNK) were measured in some animals at the end of the recordings (indicated in Fig. 5 ), either 7 min or 45 min after the last compound administration. At the terminal time-point, a blood sample was taken by heart puncture and kept in 1.6 mg EDTA/mL of blood.
Brains were stored at À80 C until they were sectioned at 40 mm in serial coronal slices that were stained with neutral red to inspect the electrode placement. Blood samples were centrifuged for 10 min at 5000 g at 4 C and plasma was stored at À80 C until analysis.
Quantitative bioanalysis
Rat plasma and brain concentrations of ketamine, norketamine and HNK were determined using ultra performance liquid chromatography coupled to tandem mass spectrometry (MS/MS). Plasma and brain concentrations of the compounds were analyzed by unpaired student t-test using SigmaPlot (version 11.0).
Results
Firing patterns of reticular, thalamic and cortical neurons
Representative examples of the firing patterns are given in Fig. 1 together with a schematic representation of the projections in the thalamo-cortical network. The mean firing rates of the recorded neurons during 5 min baseline were: 11.9 ± 2.3 spikes/s in the RtN (n ¼ 18), 1.5 ± 0.3 spikes/s in the MD/CM (n ¼ 23) and 1.5 ± 0.4 in the mPFC (n ¼ 29). In the RtN, most neurons discharged in burst firing mode. In the MD/CM, both depolarized and hyperpolarized action potentials were found. Burst episodes were characterized by doublets and triplets. Antidromically-driven cortico-thalamic pyramidal neurons exhibited a broad pattern of spontaneous activity but most units exhibited irregularly spaced bursts. These firing characteristics are consistent with those observed in previous studies (Pirot et al., 1994; Santana et al., 2011; Troyano-Rodriguez et al., 2014) . Systemic administration of vehicle did not significantly affect the firing rate or oscillatory activity in the RtN, MD/CM or mPFC (Supplementary Fig. 1 ).
Effects of ketamine on the activity of RtN
The effect of ketamine on the discharge of RtN neurons was studied in 13 rats at cumulative doses of 1, 2 and 5 mg/kg (one neuron per rat). One more rat was added for the analysis of the oscillatory activity (n ¼ 14). Ketamine significantly reduced the firing activity of RtN neurons to 61%, 65% and 37% of baseline at 1, 2 and 5 mg/kg, respectively (F 4,47 ¼ 13.16, p < 0.001, n ¼ 12e13) ( Fig. 2A) . Ketamine also significantly decreased the number of burst episodes but did not alter the burst patterns of these neurons (Supplementary Table 2A ).
In parallel with the effects on neuronal discharge, ketamine dose-dependently decreased delta (0.15e4 Hz) power to 79%, 71% and 48% of baseline, at 1, 2 and 5 mg/kg, respectively (F 4,52 ¼ 23.46, p < 0.001, n ¼ 14), whereas the power of other frequency bands remained unaltered ( Fig. 2B and C) . 
Effects of ketamine on the activity of MD/CM
The effect of ketamine on MD/CM activity was studied in 5 rats at 0.25 and 0.5 mg/kg (cumulative doses) and in 12 rats at 1, 2 and 5 mg/kg (cumulative doses; one neuron per rat). Analysis of the oscillatory activity was carried out in the same 12 rats and in one additional rat (n ¼ 13). In some rats (n ¼ 6), recordings were maintained up to 30 min after injection of the last dose in order to explore the potentially prolonged effects of the drug.
Ketamine did not significantly affect MD/CM activity at 0.25 and 0.5 mg/kg (n ¼ 5) ( Supplementary Fig. 2, A1-A2 ). However, ketamine dose-dependently reduced the firing activity of MD/CM neurons to 66%, 60% and 37% of the baseline at 1, 2 and 5 mg/kg, respectively (F 4,42 ¼ 22.79, p < 0.001, n ¼ 11e12) (Fig. 3A) . In the units examined for 30 min (n ¼ 6), the firing rate returned to baseline approximately 15 min after administration, consistent with the rapid pharmacokinetics of the drug (F 4,20 ¼ 15.84, p < 0.001, n ¼ 6) (Fig. 3B) . Ketamine (1, 2, 5 mg/kg, i.v.) significantly decreased the number of burst episodes, the number of spikes per burst and the burst duration (Supplementary Table 2B ).
In parallel, ketamine significantly increased low gamma (30e48 Hz) power to 137%, 140% and 138% of the baseline at 1, 2 and 5 mg/kg, respectively (F 4,47 ¼ 17.30, p < 0.001, n ¼ 13) (Fig. 3C ). This effect was sustained for up to 15 min post-administration of the last dose (F 7,34 ¼ 3.70, p < 0.01, n ¼ 6) ( Fig. 3D and E) . In contrast, ketamine (5 mg/kg, i.v.) evoked a significant and transient decrease of delta power to 73% of the baseline (F 4,47 ¼ 5.70, p < 0.001, n ¼ 13) (Fig. 3CeE) .
Effects of ketamine on the activity of layer VI pyramidal neurons in mPFC
The effect of ketamine on the discharge of cortico-thalamic neurons was studied in 5 rats at the dose of 0.25 mg/kg and in 15 rats at the cumulative doses of 1, 2 and 5 mg/kg (one neuron per rat). Oscillatory activity was additionally recorded with a metal electrode placed in the layer VI of the infralimbic cortex in the contralateral hemisphere. Analysis of the oscillatory activity in the 0.25 mg/kg group was done in the same 5 rats, and the effect was explored up to 40 min post-administration. In the 1, 2 and 5 mg/kg group, the analysis was carried out in 14 rats, and in 12 of them, the recordings could be maintained for up to 30 min after the last drug administration in order to explore prolonged effects of ketamine.
As in MD/CM, the low ketamine dose (0.25 mg/kg, i.v.) did not significantly affect layer VI mPFC activity (n ¼ 5) ( Supplementary  Fig. 2 B1 and B2), while it dose-dependently reduced the firing rate to 74%, 53% and 19% of the baseline at 1, 2 and 5 mg/kg, respectively (F 4,53 ¼ 8.10, p < 0.001, n ¼ 13e15) (Fig. 4A) . As in MD/ CM, the firing rate returned to baseline approximately 15 min after administration (Supplementary Table 2C ). Ketamine also decreased the number of burst episodes but did not alter the burst pattern of the recorded neurons (Supplementary Table 2C ). Ketamine evoked a transient and significant decrease of delta power (0.15e4 Hz) to 89%, 85% and 68% at 1, 2 and 5 mg/kg, respectively (F 4,52 ¼ 7.70, p < 0.001, n ¼ 14) (Fig. 4B ). Fig. 4CeD shows the temporal course of ketamine's effect (F 7,77 ¼ 5.18, p < 0.001, n ¼ 12).
In parallel, ketamine (1, 2 and 5 mg/kg, i.v.) significantly increased beta and gamma powers (12e30 Hz; 30e90 Hz, respectively) to 123%, 129%, 120% and 135%, 137%, 115% of the baseline, respectively (beta: F 4,52 ¼ 6.21, p < 0.001; gamma: F 4,52 ¼ 7.46, p < 0.001, n ¼ 14) (Fig. 4B) . Unlike for delta power, ketamine evoked a prolonged increase in beta and gamma powers that persisted for up to 30 min post-administration (beta: F 7,77 ¼ 8.07, p < 0.001; gamma F 7,77 ¼ 9.92, n ¼ 12) (Fig. 4C and D) . Similar changes on oscillatory activity were observed with glass electrode recordings ( Supplementary Fig. 3 ).
Terminal plasma and brain concentrations of ketamine and its metabolites
Plasma and brain concentrations of ketamine and its major metabolites, norketamine and HNK (Desta et al., 2012) were determined in a subgroup of animals at the end of the recordings. The concentrations of ketamine, norketamine and HNK in plasma and brain 7 and 45 min after the last cumulative dose of 5 mg/kg i.v. are given in Fig. 5 . Ketamine concentrations in plasma and brain at 45 min were lower than at 7 min post-administration (p < 0.01, unpaired student's t-test) (Fig. 5) . In contrast, HNK concentrations in plasma and brain at 45 min post-administration were significantly higher than at 7 min post-administration (p < 0.01, unpaired student's t-test). Norketamine concentrations in plasma and brain were not significantly different at the two different sampling times (n.s., unpaired student's t-test) (Fig. 5) . In brain, the main components at 7 min post-administration were ketamine and HNK (mean ketamine/HNK ratio: 2.9) whereas at 45 min, both compounds were found at comparable concentrations (mean ketamine/HNK ratio: 0.9) (Fig. 5B ).
Discussion
In the present study we show that ketamine inhibits the firing activity of thalamo-cortical networks in anesthetized rats. Ketamine dose-dependently decreased the discharge of both excitatory MD/CM relay neurons projecting to PFC as well as laver VI corticothalamic pyramidal neurons. Ketamine also suppressed the discharge of RtN GABAergic neurons known to exert tonic inhibition of the rest of the thalamus. In parallel, ketamine affected population activity in these areas, evoking a short-lasting decrease of low frequency oscillations and a more prolonged increase of gamma oscillations in MD/CM and PFC. Except in the RtN, the effects of ketamine on neuronal activity were strikingly different of those evoked by PCP, which mainly activates thalamo-cortical networks (Kargieman et al., 2007; Santana et al., 2011; TroyanoRodriguez et al., 2014 ) (see Table 1; see also Supplementary  Table 3 for details). The data from these previous PCP studies and the present ketamine study are directly comparable since they were conducted with the same experimental conditions in the same setting. Likewise, we used doses of both compounds comparable in terms of NMDA-R antagonism (Anis et al., 1983) . Importantly, the brain concentrations determined for ketamine in this study were within the range reported in clinical and preclinical studies reporting antidepressant effects (Li et al., 2011; Shaffer et al., 2014) .
Acute effect of ketamine on the activity of thalamo-cortical networks
As observed with PCP (Troyano-Rodriguez et al., 2014) and in agreement with the hyperpolarization of RtN neurons mediated by the NMDA-R antagonist APV in vitro , ketamine markedly inhibited the activity of GABAergic RtN neurons. However, in contrast to PCP (Santana et al., 2011) , this effect did not translate into an increased activity of MD/CM neurons. Instead, ketamine acutely attenuated the discharge of excitatory MD/CM neurons that mainly project to layers III and V-VI of the PFC (Kuroda et al., 1998) and of cortico-thalamic neurons in layer VI of mPFC, thus evoking an overall decrease of excitatory neurotransmission in thalamo-cortical networks.
Most cortical pyramidal and thalamic relay neurons express NMDA-Rs (Monyer et al., 1994; Wenzel et al., 1997) . Therefore, the reduction in firing rate induced by ketamine in these areas is likely Fig. 5 . Plasma and brain concentrations of ketamine and its metabolites. Bar graphs show the levels of (R,S)-ketamine (Ket) and its major metabolites (R,S)-norketamine (norKet) and (2R, 6R)-hydroxynorketamine (HNK) following ketamine i.v. administration in rats. Plasma (A) and brain (B) levels of Ket, norKet and HNK after administration of the cumulative dose of ketamine 5 mg/kg at 7 and 45 min post administration (n ¼ 3e6 per treatment group). Data are represented as average plasma (ng/ml) and brain (ng/g) concentrations ± SD. *p < 0.05.
Table 1
Comparison of the effects of PCP and ketamine on neuronal discharge in thalamo-cortical networks of the anesthetized rat. to result from a direct blockade of NMDA-Rs in the recorded neurons. This effect would counteract the disinhibition of thalamocortical pathways resulting from the blockade of NMDA-R in RtN GABA neurons (see scheme in Fig. 6 ). These effects are entirely different from those evoked by PCP (see Table 1 ) and from studies on MK-801 in the mPFC of awake rats (Homayoun and Moghaddam, 2007) . The net effect of any given NMDA-R antagonist on thalamocortical neurons is determined by the balance between the inhibitory effect induced by NMDA-R blockade in the recorded unit and the disinhibition evoked by NMDA-Rs located on GABAergic elements controlling thalamic and cortical activity (e.g., GABA interneurons in PFC, projection GABA neurons in RtN and basal ganglia structures, see scheme in Fig. 6 ). The comparable actions of PCP and ketamine on RtN neurons -yet strikingly different in MD/ CM and mPFC-suggest a similar action on NMDA-R located on RtN GABA neurons and remarkable differences in their interaction with thalamic and cortical NMDA-R.
Ketamine, MK-801 and PCP essentially are non-selective antagonists of the different GluN1/2 NMDA-R subtypes (Dravid et al., 2007; Yamakura et al., 1993) . However, ketamine exhibits some preference for recombinant GluN2C-and 2D-containing receptors (Khlestova et al., 2016; Kotermanski and Johnson, 2009) . Given the preferential expression of the GluN2C subunits in thalamus (Karavanova et al., 2007; Monyer et al., 1994; Wenzel et al., 1997) this might partly explain a preferential NMDA-R blockade by ketamine in MD/CM, which would compensate the effects of RtN disinhibition. Likewise, PCP-ketamine differences in voltage dependency (Davies et al., 1988; Gilling et al., 2009; MacDonald et al., 1991) or a differential interaction with chloral hydrate anesthesia may also contribute. In contrast, it is unlikely that ketamine metabolites can account for the difference since (2S,6S; 2R, 6R)-HNK activates AMPA-R mediated synaptic transmission (Zanos et al., 2016) .
In agreement with the present observations, ketamine reduces metabolic activity in thalamic nuclei of mice, including RtN and MD, in parallel with an increased activity of upper cortical layers (I-III) of the mPFC (Dawson et al., 2013 (Dawson et al., , 2014 . In contrast, neuroimaging studies in humans and non-human primates show that ketamine increases glucose metabolism in the cingulate cortex and the thalamus Downey et al., 2016; Doyle et al., 2013; Maltbie et al., 2016; Vollenweider and Kometer, 2010) . These discrepancies are not fully understood and may depend on several factors, including i) species differences, perhaps related to the presence of thalamic interneurons in primate and human brains, but not in rodent brain, except for the lateral geniculate nucleus (Arcelli et al., 1997; Ohara et al., 1983) , ii) differential cellular and target selectivity of ketamine at the very Fig. 6 . Schematic representation of thalamo-cortical connectivity (modified after Troyano-Rodriguez et al., 2014) with representative examples of the effect of ketamine on neuronal discharge in each of the areas examined. Ketamine induced a dramatic reduction of the discharge of GABAergic RtN neurons that tonically inhibit excitatory thalamic nuclei. Despite the reduced GABAergic inputs onto MD/CM neurons resulting from ketamine's effect on RtN neurons, ketamine reduced the neuronal discharge in these thalamic nuclei, as well as in layer VI pyramidal neurons of the mPFC which project to thalamic excitatory (MD/CM among others) and inhibitory (RtN) nuclei. The activity of excitatory thalamic nuclei is also controlled by GABAergic structures of the basal ganglia circuit, such as ventral pallidum and substantia nigra reticulata (not examined in the present study). different doses, routes and infusion rates used in these studies, iiii) variable concentrations of ketamine and metabolites at the different time points reported in the above studies and, iv) the use of anesthesia in some studies, which alters the effect of ketamine on glucose metabolism (Littlewood et al., 2006) .
Together with the decrease in neuronal discharge, ketamine transiently decreased delta (0.15e4 Hz) power in the RtN, MD/CM and mPFC (IL cortex), as also observed for PCP (Kargieman et al., 2007; Neal and Bond, 1985; Santana et al., 2011; TroyanoRodriguez et al., 2014) . Delta oscillations reflect synchronized activity changes of neuronal networks and are generated by neocortical and thalamo-cortical networks (Steriade et al., 1993; Timofeev and Chauvette, 2011) . Interestingly, the acute reductions in delta power mediated by ketamine are short-lasting, reflecting its fast pharmacokinetics and most likely related to it psychotomimetic activity (Zarate et al., 2006) . In support of this view, the reduction in delta power induced by PCP is reversed by marketed and experimental antipsychotic drugs (Kargieman et al., 2007; Llado-Pelfort et al., 2016; Santana et al., 2011; Troyano-Rodriguez et al., 2014) .
Prolonged effect of ketamine on thalamo-cortical activity
The increase in gamma oscillations produced by ketamine in mPFC and MD/CM was observed throughout the recording period, long exceeding the fall in delta oscillations and thus suggesting its lack of association to the short-lasting psychotomimetic effects.
NMDA-R antagonists also increase gamma power in the cortex of anesthetized and freely moving animals (Hakami et al., 2009; Hiyoshi et al., 2014; Kittelberger et al., 2012; Phillips et al., 2012; Pinault, 2008; Sanacora et al., 2014; Wood et al., 2012; Zanos et al., 2016) . Gamma oscillations reflect local cell assembly organization in cortical networks. They depend on the activation of ionotropic excitatory receptors and are therefore considered to reflect neuronal excitation/disinhibition (Buzsaki and Draguhn, 2004; Cunningham et al., 2003; Whittington et al., 2000) . Therefore, the ketamine-induced increase of gamma oscillations in mPFC (in particular, IL) may be taken as a surrogate measure of neuronal excitability. Given the inhibition of thalamo-cortical circuits by ketamine, the increase in gamma oscillations should be driven by other mechanisms, such as blockade of NMDA-Rs in local fastspiking GABAergic interneurons (Cardin et al., 2009; Carlen et al., 2012) and the subsequent increase in pyramidal neuron activity (Hanson et al., 2013; Homayoun and Moghaddam, 2007; Jackson et al., 2004; Quirk et al., 2009) . However, these effects should occur in cortical layers other than layer VI, with different afferent and efferent connectivity (Gabbott et al., 2005) .
The temporal dissociation between the effect of ketamine on delta and gamma oscillations (with more persistent effects on the latter band) is reminiscent of the i.v. effects of ketamine in patients, with a persistent antidepressant effect by the end of the psychotomimetic phase (Zarate et al., 2006) . HNK has been suggested to mediate the delayed antidepressant effect through the activation of AMPA-Rs (Zanos et al., 2016 ) although a very recent study indicates that HNK also blocks synaptic NMDA-R function (Suzuki et al., 2017) . Interestingly, the increase in gamma power occurs after a switch in the relative concentration of ketamine and its metabolites with the HNK/ketamine ratio in brain being higher 45 min than that 7 min after administration. This observation is consistent with Zanos et al. (2016) , showing that HNK administration may increase gamma power in mouse cortex. Overall, despite the limited time window used, these findings suggest a temporal association between the increase in gamma power and the antidepressant-like effects of ketamine, inasmuch as the NMDA-R-antagonist-induced gamma oscillations could not be prevented by antipsychotic drugs . However, further investigations are needed to validate this variable as a potential biomarker.
Limitations of the study
The two main limitations of the present study are the use of anesthesia and the limited time window used to assess ketamine's actions. Both are inter-related since single unit recordings cannot be performed for prolonged periods of time in anesthetized rodents. As discussed above, chloral hydrate anesthesia may alter the excitatory/inhibitory balance and therefore, alter the cellular selectivity of NMDA-R antagonists including ketamine. Future studies in freely-moving rats will overcome some of these limitations and allow the assessment of the persistent antidepressant effects of ketamine.
Conclusions
In summary, the present study indicates that ketamine evokes a prominent fast and short-lasting decrease of the activity of thalamo-cortical circuits together with a decrease in delta oscillations, followed by a persistent increase of gamma oscillations. Short-lasting effects may be related to psychotomimetic actions, which follow the rapid pharmacokinetics of ketamine, whereas the prolonged increase in gamma oscillations may tentatively be ascribed to its persistent antidepressant effects, which emerge after the end of the psychotomimetic phase. The remarkable differences with PCP support a different target selectivity of both agents, at least in the anesthetized rat. Future work will determine the relationship of the present findings to the psychotomimetic and antidepressant effects of ketamine.
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